Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Open-Angle Glaucoma Clear all
Completed Phase 1 Interventional

Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT04188015
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
2.5mg ANX007, 5.0mg ANX007, Sham Procedure
Biological · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Newport Beach, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jun 26, 2026, 11:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Efficacy of Selective Laser Trabeculoplasty

NCT00347893
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pseudo-Exfoliative Glaucoma, Pigment Dispersion Glaucoma
Interventions
Selective laser trabeculoplasty
Procedure
Lead sponsor
Glaucoma Research & Education Group
Other
Eligibility
0 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Jun 26, 2026, 11:03 AM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG) Patient
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

NCT02036541
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
AqueSys XEN 45 Glaucoma Implant
Device
Lead sponsor
AqueSys, Inc.
Industry
Eligibility
45 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

NCT01560975
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Jun 26, 2026, 11:03 AM EDT
Terminated No phase listed Observational

Development and Validation of a Model to Predict Fast Progression in Glaucoma

NCT04454190
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions
Collection of genetic material
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
40 Years to 90 Years
Enrollment
1,152 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jun 26, 2026, 11:03 AM EDT
Terminated Not applicable Interventional

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312
View directory record Official record
Conditions
Primary Open-Angle Glaucoma
Interventions
Stents, Laser, Laser Trabeculoplasty
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

NCT01693315
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Jun 26, 2026, 11:03 AM EDT
Completed No phase listed Observational Results available

An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

NCT04872348
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Atlanta, Georgia • Wichita, Kansas • Bloomington, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT03488550
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
ANX007
Biological
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jun 26, 2026, 11:03 AM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

NCT00824824
View directory record Official record
Conditions
Glaucoma
Interventions
Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Safety and Feasibility of the ELIOS System in POAG Patients

NCT05999006
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

NCT01915940
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Jun 26, 2026, 11:03 AM EDT
Completed No phase listed Observational Results available

Open Label Extension of LipoLat-CS202

NCT02599688
View directory record Official record
Conditions
Glaucoma
Interventions
Observation only
Other
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device

NCT02016898
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Placement of the sponge, Mitomycin-C
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

The Effects of an Antioxidant Formulation on Ocular Blood Flow

NCT01930487
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
dietary supplement with antioxidants, Placebo
Dietary Supplement
Lead sponsor
ScienceBased Health
Industry
Eligibility
30 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

NCT02023242
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, iStent Trabecular Micro Bypass
Device
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years to 84 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

NCT02143843
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

NCT04284514
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jun 26, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01410188
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
OPA-6566, Placebo, Latanoprost
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Artesia, California • Glendale, California • Roswell, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Jun 26, 2026, 11:03 AM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

NCT06313749
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions
Minimally Invasive Micro Sclerostomy Device
Device
Lead sponsor
Sanoculis Ltd
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jun 26, 2026, 11:03 AM EDT
Recruiting Not applicable Interventional

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

NCT05844384
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Nanodropper, Regular dropper
Device
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jun 26, 2026, 11:03 AM EDT